Clinical Trial: Study of DT-7012 As a Single Agent and in Combination with an Immune Checkpoint Inhibitor in Participants with Advanced Solid Tumors

U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT06819735) titled 'Study of DT-7012 As a Single Agent and in Combination with an Immune Checkpoint Inhibitor in Participants with Advanced Solid Tumors' on Feb. 06.

Brief Summary: This is a phase 1/2, dose-escalation and cohort-expansion clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of DT-7012 (an anti-CCR8 monoclonal antibody) as a single agent and in combination with an immune checkpoint inhibitor in adult participants with selected advanced solid tumors.

Study Start Date: June, 2025

Study Type: INTERVENTIONAL

Condition: Advanced Solid Tumors

Intervention: DRUG: DT-7012

Intravenous infusi...